FierceBiotech

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement

XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...
Monthly Prescribing Reference

Xarelto Approved to Treat and Prevent Blood Clots in Pediatric Patients

A new oral suspension formulation of Xarelto has also been approved by the FDA. The Food and Drug Administration (FDA) has approved Xarelto ® (rivaroxaban) for 2 new pediatric indications: treatment ...
The Trentonian

Janssen Submits New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

RARITAN, N.J., June 23, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug ...
FierceBiotech

Bayer's Xarelto Approved in Canada

First approval for Bayer's new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral, direct ...
TCTMD

Rivaroxaban May Help Dissolve Left Atrial Thrombus in Patients With A-fib

Providing validation to what many physicians are already doing, a new study suggests that non-vitamin K antagonist oral anticoagulants (NOACs)—rivaroxaban, in particular—are effective alternatives to ...
FiercePharma

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement

Raritan, NJ (July 1, 2011) - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral ...